David R Matthews
David R Matthews
Professor of Diabetes, University of Oxford
Η διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα ocdem.ox.ac.uk
Τίτλος
Παρατίθεται από
Παρατίθεται από
Έτος
Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
DR Matthews, JP Hosker, AS Rudenski, BA Naylor, DF Treacher, ...
diabetologia 28 (7), 412-419, 1985
307041985
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
UK Prospective Diabetes Study (UKPDS) Group
The lancet 352 (9131), 837-853, 1998
200931998
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton, AI Adler, HAW Neil, DR Matthews, SE Manley, CA Cull, ...
Bmj 321 (7258), 405-412, 2000
106512000
Heart disease and stroke statistics—2017 update: a report from the American Heart Association
EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ...
circulation 135 (10), e146-e603, 2017
101952017
10-year follow-up of intensive glucose control in type 2 diabetes
RR Holman, SK Paul, MA Bethel, DR Matthews, HAW Neil
New England journal of medicine 359 (15), 1577-1589, 2008
81622008
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
UK Prospective Diabetes Study (UKPDS) Group
The Lancet 352 (9131), 854-865, 1998
80361998
Use and abuse of HOMA modeling
TM Wallace, JC Levy, DR Matthews
Diabetes care 27 (6), 1487-1495, 2004
45372004
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the …
SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ...
Diabetes Spectrum 25 (3), 154-171, 2012
40522012
Canagliflozin and cardiovascular and renal events in type 2 diabetes
B Neal, V Perkovic, KW Mahaffey, D De Zeeuw, G Fulcher, N Erondu, ...
New England Journal of Medicine 377 (7), 644-657, 2017
37862017
Publication bias in clinical research
PJ Easterbrook, R Gopalan, JA Berlin, DR Matthews
The Lancet 337 (8746), 867-872, 1991
30901991
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European …
SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ...
Diabetes care 38 (1), 140-149, 2015
28872015
American heart association statistics committee and stroke statistics subcommittee
EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ...
Heart disease and stroke statistics-2017 update: a report from the American …, 2017
2859*2017
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
AI Adler, IM Stratton, HAW Neil, JS Yudkin, DR Matthews, CA Cull, ...
Bmj 321 (7258), 412-419, 2000
27722000
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)
RC Turner, H Millns, HAW Neil, IM Stratton, SE Manley, DR Matthews, ...
Bmj 316 (7134), 823-828, 1998
26501998
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the …
SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ...
Diabetologia 55 (6), 1577-1596, 2012
2484*2012
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone ...
The Lancet 368 (9541), 1096-1105, 2006
20112006
Correct homeostasis model assessment (HOMA) evaluation uses the computer program
JC Levy, DR Matthews, MP Hermans
Diabetes care 21 (12), 2191-2192, 1998
19021998
UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease
UK Prospective Diabetes Study Group
Diabetes 44 (11), 1249-1258, 1995
16871995
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in …
M Nauck, A Frid, K Hermansen, NS Shah, T Tankova, IH Mitha, ...
Diabetes care 32 (1), 84-90, 2009
13902009
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
RJ Stevens, V Kothari, AI Adler, IM Stratton, RR Holman, ...
Clinical science 101 (6), 671-679, 2001
12842001
Δεν είναι δυνατή η εκτέλεση της ενέργειας από το σύστημα αυτή τη στιγμή. Προσπαθήστε ξανά αργότερα.
Άρθρα 1–20